RNS Number : 1309T
OptiBiotix Health PLC
16 July 2020

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Extension of terms, territories and products with CTC Holding BV
Probiotix Health Ltd expands agreement

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its fully-owned subsidiary ProBiotix Health Ltd ("ProBiotix"), has extended the terms, territories, and products from its distribution agreement (RNS: 9 December 2019) with CTC Holding BV ("CTC") known as the CTC Group (http://www.ctc-group.com/) for the sale of CholBiome$_{X3}$.

The new agreement:-

- Extends the product range from the distribution of CholBiome$_{X3}$ to include LP$_{LDL}$®, as bulk ingredient and three additional products: CholBiome, CholBiome$_{BP}$ and CholBiome$_{VH}$
- Extends the number of territories from the Philippines to include non-exclusive distribution rights for Vietnam, Indonesia, Colombia, the Dominican Republic and Guatemala

The agreement is for an initial period of 24 months and has minimum order quantities for each product and country with a three year business plan and forecast to allow production planning.

CTC is the global business network group of the Koen Visser Corporation with its head office located in Amsterdam, The Netherlands. CTC is a global life science partner-provider of innovative product solutions for food, beverage, personal care products and health & wellness.

This agreement recognises and rewards the success of CTC Far East Philippines, Inc. in its launch and distribution of CholBiome®$_{X3}$ in the Philippines. This is another important step, in this case with an existing partner, in building the LP$_{LDL}$® brand in more territories around the world. Brand recognition builds customer loyalty and enhances product value, as illustrated by Christians Hansens acquisition of Valio's LGG® brand. See link here: https://www.chr-hansen.com/en/media/2016/9/to-further-strengthen-its-probiotics-offering-chr-hansen-acquires-lgg-the-worlds-best-documente

Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Ltd commented: *"We are pleased to announce the extension of terms, territory, and product range for CTC. The agreement recognises the success of CTC with CholBiome$_{X3}$ in the Philippines and extends the terms, territory, and product range to support sales growth. This is another step in extending the geographical reach of LP$_{LDL}$® as an ingredient and in final product to build recurring revenue streams and brand recognition across more and more territories around the world."*

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUVSVRRBUBAAR